Association between nonsteroidal anti-inflammatory drugs use and risk of central nervous system tumors: a dose-response meta analysis.

Tao Zhang,Xiaowen Yang,Jie Luo,Hui Wang,Yi Zhou,Pei Liu,Anrong Li,Jianrui Zhou

doi:10.18632/oncotarget.21829

Tao Zhang, Xiaowen Yang + Show 6 more

Open Access

https://doi.org/10.18632/oncotarget.21829

Copy DOI

Journal: Oncotarget	Publication Date: Oct 11, 2017
Citations: 10	License type: cc-by

Affiliation: Hubei University of Medicine

Abstract

Although studies have examined the association between nonsteroidal anti-inflammatory drugs (NSAIDs) use and central nervous system (CNS) tumors risk, the results are inconclusive. Here, we conducted a dose-response meta-analysis in order to investigate the correlation between NSAIDs use and CNS tumors risk. Up to July 2017, 12 studies were included in current meta-analysis. NSAIDs use was significantly associated with a lower risk of CNS tumors. Furthermore, non-aspirin NSAIDs or aspirin use are significantly associated with a lower risk of CNS tumors. Additionally, NSAIDs use was associated with significantly a lower risk of glioma, glioblastoma but not meningioma. Subgroup analysis showed consistent findings. Furthermore, a significant dose-response relationship was observed between NSAIDs use and CNS tumors risk. Increasing cumulative 100 defined daily dose of NSAIDs use was associated with a 5% decrement of CNS tumors risk, increasing NSAIDs or non-aspirin NSAIDs or aspirin use (per 3 prescriptions increment) was associated with a 7%, 7%, 10% decrement of CNS tumors risk, increasing per 2 year of duration of NSAIDs or non-aspirin NSAIDs or aspirin use was associated with a 6%, 8%, 6% decrement of CNS tumors risk. Considering these promising results, NSAIDs use might provide helpful for reducing CNS tumors risk. Large sample size and different ethnic population are warranted to validate this association.

Highlights

Central nervous system (CNS) tumors are the second leading cause of death from neurological diseases worldwide, and costs on patients, caregivers and society [1]
Increasing cumulative 100 defined daily dose of nonsteroidal antiinflammatory drugs (NSAIDs) use was associated with a 5% decrement of central nervous system (CNS) tumors risk, increasing NSAIDs or non-aspirin NSAIDs or aspirin use was associated with a 7%, 7%, 10% decrement of CNS tumors risk, increasing per 2 year of duration of NSAIDs or non-aspirin NSAIDs or aspirin use was associated with a 6%, 8%, 6% decrement of CNS tumors risk
Twenty-two reports investigated the association between non-aspirin NSAIDs use and CNS tumors risk, eleven reports investigated the association between aspirin use and CNS tumors risk

Summary

INTRODUCTION

Central nervous system (CNS) tumors are the second leading cause of death from neurological diseases worldwide, and costs on patients, caregivers and society [1]. Survival chances have improved gradually over the last 30 years but remain poor compared to many other cancers, and 30% glioma survived to one year and 15% glioma survived to five years of patients after diagnosis in adults [2, 3]. These data reveal the poor prognosis of CNS tumors, and to prevent the occurrence of CNS tumors is essential. Previous studies investigating have showed nonsteroidal anti-inflammatory drugs (NSAIDs) have a chemopreventive potential in the CNS tumors in vitro and in vivo [5]. We performed this dose-response meta-analysis to clarify and quantitative assessed the correlation between NSAIDs use and CNS tumors risk

Literature search results

DISCUSSION

Study design Country

MATERIALS AND METHODS

Study design